Inflation Reduction Act impact on the hematology/oncology treatment landscape.

The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medications, with significant implications for hematology and oncology treatment. This commentary explores the potential clinical impact of the IRA on selected cancer therapies and cancer-related supportive care agents, including apixaban (Eliquis), rivaroxaban (Xarelto), ibrutinib (Imbruvica), acalabrutinib (Calquence), enzalutamide (Xtandi), palbociclib (Ibrance), and pomalidomide (Pomalyst). These agents, used across various cancer types including chronic lymphocytic leukemia, prostate cancer, breast cancer, and multiple myeloma, are central to current treatment paradigms and have high utilization among the Medicare population. The IRA's negotiated pricing may improve drug affordability and access, influence prescribing patterns, and shift prescribing practice. However, clinical considerations, including efficacy, toxicity profiles, and overall survival benefits, remain critical in guiding therapeutic decisions. As cost-effectiveness analyses evolve in response to pricing changes, the IRA may ultimately reshape the oncology treatment landscape by aligning economic value with patient-centered care.